Biofinancing

The Best Biotech IPO Window

...That Money Can Buy!

Mark Edwards Mark Edwards
With 46 biotech companies completing their initial public offering (IPO) on US exchanges in 2017, the current IPO Window has now been open for an unprecedented five years. This presentation reviews the trends, favorable and ominous, associated with the 2017 cohort. In addition, the downloadable spreadsheets contain links to the IPO prospectuses for all 276 biotechs that have gone public since early 2013.
View Attached Document